UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 79

Sortiert nach

Mutations and prognosis in primary myelofibrosis

Leukemia, 2013-09, Vol.27 (9), p.1861-1869

2013

Volltextzugriff (PDF)

The number of prognostically detrimental mutations and prognosis in primary myelofibrosis: an international study of 797 patients

Leukemia, 2014-09, Vol.28 (9), p.1804-1810

2014

Volltextzugriff (PDF)

Risk factors for arterial versus venous thrombosis in polycythemia vera: a single center experience in 587 patients

Blood cancer journal (New York), 2017-12, Vol.7 (12), p.662-662, Article 662

2017

Volltextzugriff (PDF)

Prognostic significance of ASXL1 mutation types and allele burden in myelofibrosis

Leukemia, 2018-03, Vol.32 (3), p.837-839

2018

Volltextzugriff (PDF)

Calreticulin mutations and long-term survival in essential thrombocythemia

Leukemia, 2014-12, Vol.28 (12), p.2300-2303

2014

Volltextzugriff (PDF)

Application of current prognostic models for primary myelofibrosis in the setting of post-polycythemia vera or post-essential thrombocythemia myelofibrosis

Leukemia, 2017-12, Vol.31 (12), p.2851-2852

2017

Volltextzugriff (PDF)

Prognostic interaction between ASXL1 and TET2 mutations in chronic myelomonocytic leukemia

Blood cancer journal (New York), 2016-01, Vol.6 (1), p.e385-e385

2016

Volltextzugriff (PDF)

Predictors of survival in WHO-defined hypereosinophilic syndrome and idiopathic hypereosinophilia and the role of next-generation sequencing

Leukemia, 2016-09, Vol.30 (9), p.1924-1926

2016

Volltextzugriff (PDF)

Refined cytogenetic-risk categorization for overall and leukemia-free survival in primary myelofibrosis: a single center study of 433 patients

Leukemia, 2011-01, Vol.25 (1), p.82-88

2011

Volltextzugriff (PDF)

TET2 mutations and their clinical correlates in polycythemia vera, essential thrombocythemia and myelofibrosis

Leukemia, 2009-05, Vol.23 (5), p.905-911

2009

Volltextzugriff (PDF)

Incidence and risk factors for bleeding in 1104 patients with essential thrombocythemia or prefibrotic myelofibrosis diagnosed according to the 2008 WHO criteria

Leukemia, 2012-04, Vol.26 (4), p.716-719

2012

Volltextzugriff (PDF)

MPL mutations and palpable splenomegaly are independent risk factors for fibrotic progression in essential thrombocythemia

Blood cancer journal (New York), 2016-10, Vol.6 (10), p.e487-e487

2016

Volltextzugriff (PDF)

Flow cytometry based monocyte subset analysis accurately distinguishes chronic myelomonocytic leukemia from myeloproliferative neoplasms with associated monocytosis

Blood cancer journal (New York), 2017-07, Vol.7 (7), p.e584-e584

2017

Volltextzugriff (PDF)

European LeukemiaNet-defined primary refractory acute myeloid leukemia: the value of allogeneic hematopoietic stem cell transplant and overall response

Blood cancer journal (New York), 2022-01, Vol.12 (1), p.7-8, Article 7

2022

Volltextzugriff (PDF)

Vascular events and risk factors for thrombosis in refractory anemia with ring sideroblasts and thrombocytosis

Leukemia, 2016-11, Vol.30 (11), p.2273-2275

2016

Volltextzugriff (PDF)

Core-binding factor acute myeloid leukemia: long-term outcome of 70 patients uniformly treated with "7+3"

Blood cancer journal (New York), 2022-04, Vol.12 (4), p.55-55, Article 55

2022

Volltextzugriff (PDF)

The JAK2 46/1 haplotype confers susceptibility to essential thrombocythemia regardless of JAK2V617F mutational status-clinical correlates in a study of 226 consecutive patients

Leukemia, 2010-01, Vol.24 (1), p.110-114

2010

Volltextzugriff (PDF)

Risk stratification for survival and leukemic transformation in essential thrombocythemia: a single institutional study of 605 patients

Leukemia, 2007-02, Vol.21 (2), p.270-276

2007

Volltextzugriff (PDF)

Prognostic relevance of lymphocytopenia, monocytopenia and lymphocyte-to-monocyte ratio in primary myelodysplastic syndromes: a single center experience in 889 patients

Blood cancer journal (New York), 2017-03, Vol.7 (3), p.e550-e550

2017

Volltextzugriff (PDF)

Prognostic impact of bone marrow fibrosis in polycythemia vera: validation of the IWG-MRT study and additional observations

Blood cancer journal (New York), 2017-03, Vol.7 (3), p.e538-e538

2017

Volltextzugriff (PDF)

WHO-defined 'myelodysplastic syndrome with isolated del(5q)' in 88 consecutive patients: survival data, leukemic transformation rates and prevalence of JAK2, MPL and IDH mutations

Leukemia, 2010-07, Vol.24 (7), p.1283-1289

2010

Volltextzugriff (PDF)

Number and type of TET2 mutations in chronic myelomonocytic leukemia and their clinical relevance

Blood cancer journal (New York), 2016-09, Vol.6 (9), p.e472-e472

2016

Volltextzugriff (PDF)

P775: CLINICAL OUTCOMES AND SOCIOECONOMIC FACTORS IN CHRONIC MYELOMONOCYTIC LEUKEMIA IN THE UNITED STATES USING THE NATIONAL CANCER DATABASE: 2004‐2017

HemaSphere, 2022-06, Vol.6, p.670-671

2022

Volltextzugriff (PDF)

Survival trends in primary myelodysplastic syndromes: a comparative analysis of 1000 patients by year of diagnosis and treatment

Blood cancer journal (New York), 2016-04, Vol.6 (4), p.e414-e414

2016

Volltextzugriff (PDF)

IDH mutations and trisomy 8 in myelodysplastic syndromes and acute myeloid leukemia

Leukemia, 2010-12, Vol.24 (12), p.2120-2122

2010

Volltextzugriff (PDF)

1 – 25 von 79

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(75)
Mit Volltextzugriff
(77)

Publikationsform

Artikel
(78)
Berichte
(1)

Sprache

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(2)

Menü

Weitere Dienste

Einstellungen

Mutations and prognosis in primary myelofibrosis

The number of prognostically detrimental mutations and prognosis in primary myelofibrosis: an international study of 797 patients

Risk factors for arterial versus venous thrombosis in polycythemia vera: a single center experience in 587 patients

Prognostic significance of ASXL1 mutation types and allele burden in myelofibrosis

Calreticulin mutations and long-term survival in essential thrombocythemia

Application of current prognostic models for primary myelofibrosis in the setting of post-polycythemia vera or post-essential thrombocythemia myelofibrosis

Prognostic interaction between ASXL1 and TET2 mutations in chronic myelomonocytic leukemia

Predictors of survival in WHO-defined hypereosinophilic syndrome and idiopathic hypereosinophilia and the role of next-generation sequencing

Refined cytogenetic-risk categorization for overall and leukemia-free survival in primary myelofibrosis: a single center study of 433 patients

TET2 mutations and their clinical correlates in polycythemia vera, essential thrombocythemia and myelofibrosis

Incidence and risk factors for bleeding in 1104 patients with essential thrombocythemia or prefibrotic myelofibrosis diagnosed according to the 2008 WHO criteria

MPL mutations and palpable splenomegaly are independent risk factors for fibrotic progression in essential thrombocythemia

Flow cytometry based monocyte subset analysis accurately distinguishes chronic myelomonocytic leukemia from myeloproliferative neoplasms with associated monocytosis

European LeukemiaNet-defined primary refractory acute myeloid leukemia: the value of allogeneic hematopoietic stem cell transplant and overall response

Vascular events and risk factors for thrombosis in refractory anemia with ring sideroblasts and thrombocytosis

Core-binding factor acute myeloid leukemia: long-term outcome of 70 patients uniformly treated with "7+3"

The JAK2 46/1 haplotype confers susceptibility to essential thrombocythemia regardless of JAK2V617F mutational status-clinical correlates in a study of 226 consecutive patients

Risk stratification for survival and leukemic transformation in essential thrombocythemia: a single institutional study of 605 patients

Prognostic relevance of lymphocytopenia, monocytopenia and lymphocyte-to-monocyte ratio in primary myelodysplastic syndromes: a single center experience in 889 patients

Prognostic impact of bone marrow fibrosis in polycythemia vera: validation of the IWG-MRT study and additional observations

WHO-defined 'myelodysplastic syndrome with isolated del(5q)' in 88 consecutive patients: survival data, leukemic transformation rates and prevalence of JAK2, MPL and IDH mutations

Number and type of TET2 mutations in chronic myelomonocytic leukemia and their clinical relevance

P775: CLINICAL OUTCOMES AND SOCIOECONOMIC FACTORS IN CHRONIC MYELOMONOCYTIC LEUKEMIA IN THE UNITED STATES USING THE NATIONAL CANCER DATABASE: 2004‐2017

Survival trends in primary myelodysplastic syndromes: a comparative analysis of 1000 patients by year of diagnosis and treatment

IDH mutations and trisomy 8 in myelodysplastic syndromes and acute myeloid leukemia

Suchergebnisse filtern